Cantitate/Preț
Produs

Cell Therapy: cGMP Facilities and Manufacturing

Editat de Adrian P. Gee
en Limba Engleză Hardback – 11 noi 2021
This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. 

Citește tot Restrânge

Preț: 111684 lei

Preț vechi: 136201 lei
-18% Nou

Puncte Express: 1675

Preț estimativ în valută:
21384 22267$ 17742£

Carte tipărită la comandă

Livrare economică 13-27 februarie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783030755355
ISBN-10: 3030755355
Pagini: 692
Ilustrații: X, 692 p. 107 illus., 75 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 1.23 kg
Ediția:2nd ed. 2022
Editura: Springer International Publishing
Colecția Springer
Locul publicării:Cham, Switzerland

Cuprins

Part 1.     Regulatory1.  Regulation of Cell Therapy in the United States 
2.   Regulatory Landscape and Emerging Trends In Advanced Therapies Manufacturing: An EU Perspective 
3.   Australian Cellular Therapy Regulations 
4.   Landscape for Regenerative Medicine Manufacturing in Japan 
5.   GLP Regulations for Non-clinical studies 
6.  Ethical Considerations in Cell Therapy 
7.  Investigational New Drug Applications for Cell Therapy Products
8.   FDA Inspections 
9.   Commercialization of Investigational Cell Therapy Products 
Part 2   Quality Systems
10.  The Meaning of Quality 
11.   Development and Maintenance of a Quality Program
12.   Quality Control of Cellular Therapy Products and Viral Vectors 
13.   Quality Management Software – Q-Pulse 
14.   Selection of Contract Manufacturing and Testing Organizations 
Part 3     Facility Design
15.   Introduction: Facility Design 
16.   PACT CPFs - Examples Describing Different Cell Processing Facility Designs
17. Design and Operation of a Multiuse GMP Facility at the City of Hope 
18. Design and Operation of a Multiuse GMP Facility at the University of Miami 
19.   Design of a New Academic GMP Facility for Today and Beyond at the Dana-Farber Cancer Institute
20.  Design and Licensure of an American Cord Blood Bank 
21.   Indiana University Vector Production Facility (IUVPF) 
22.   Qualification and Commissioning of a New GMP Facility 
Part 4    Facility Infrastructure
23.   Environmental Monitoring 
24.   GMP Facility Cleaning and Maintenance 
25.  GMP Documentation 
26.   Process Validation 
27.   Equipment Qualification 
28.  Vendor Qualification and Supply Management 
29.  Staffing, Training and Competency 
Part 5    Product Management
30.   Product Accessioning, Tracing and Tracking 
31.   ISBT 128 in Labeling of Cellular Therapy Products 
32.   Product Processing, Manufacturing and Administration 
33.   Transport and Shipment of Cellular and Gene Therapy Products 
34.    Regenerative Medicine: The Newest Cellular Therapy
35.     Cellular Therapy Applications for COVID-19 
Part 6    Professional Standards and Support Organizations
36.   Professional Standards for Cellular Therapy: The Foundation for the Accreditation of Cellular Therapy (FACT) 
37.   AABB Cell Therapy Standards
38.  USP Standards for Cell-based Therapies
39.   The Role of the National Institute of Standards Measurement Assurance for Cell Therapies
40.  National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT) 
41.  Financial Considerations for Academic GMP Facilities 
42.  Governmental Support Opportunities for Cellular & Gene Therapies in the United States 

Notă biografică

Dr. Adrian Gee is currently Professor of Medicine & Pediatrics, Center for Cell & Gene Therapy at Baylor College of Medicine. He received his bachelor’s degree from the University of Birmingham, England, and his Ph.D. from the University of Edinburgh, Scotland. He completed postdoctoral training at the National Institutes of Health and the University of Toronto. He then joined the faculty at the University of Florida where he performed some of the first applications of immunomagnetic tumor purging in the United States, and his laboratory became a central cell processing facility for this procedure. He co-founded the International Society for Hematotherapy and Graft Engineering (ISHAGE, now ISCT), and the Journal of Hematotherapy (now Cytotherapy) and helped establish the stem cell transplantation program at the University of South Carolina. He then directed the Cell Processing Laboratory at the University of Texas MD Anderson Cancer Center until he joined the Center for Cell and Gene Therapy (CAGT) at Baylor College of Medicine in Houston. The CAGT houses GMP manufacturing facilities for vectors and cell therapy products, and has been selected as one of the 5 national somatic cell therapy processing centers by the National Heart, Lung & Blood Institute. Dr. Gee was involved in the development of standards for the collection processing and transplantation of hematopoietic stem cells for the Foundation for the Accreditation of Cell Therapy (FACT), the American Association of Blood Banks and the National Marrow Donor Program.

Textul de pe ultima copertă

This new edition presents a fully-updated and expanded look at current Good Manufacturing Practice (cGMP) for cell therapy products. It provides a complete discussion of facility design and operation including details specific to cord blood banking, cell processing, vector production and qualification of a new facility. Several chapters cover facility infrastructure including cleaning and maintenance, vendor qualification, writing a Standard Operating Procedure, staff training, and process validation. The detailed and invaluable product information covers topics like labelling, release and administration, transportation and shipment, et al. Further chapters cover relevant topics like writing and maintaining investigational new drug applications, support opportunities in North America and the European Union, commercial cell processing and quality testing services, and financial considerations for academic GMP facilities. A chapter on future directions rounds out Cell Therapy: cGMP Facilities and Manufacturing making it essential reading for any cell therapy professional involved in the development, use, or management of this type of facility. 


Caracteristici

Fully updated and expanded second edition reflects all recent developments and changes in the field
Comprehensive coverage of essential information from ethical considerations and facility management to product tracing and labeling, staff training and much more
Covers other essential topics like quality management, professional standards, writing/maintaining Standard Operating Procedures, financial considerations for academic facilities, future directions, etc